The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Results of an economic analysis, based on safety and efficacy data from 2 randomized phase 3 trials that evaluated upfront maintenance with bevacizumab or upfront maintenance with olaparib in women with newly diagnosed advanced BRCA-mutant ovarian cancer, as well as the direct and indirect costs associated with administering these medications in this setting, suggest that the administration of olaparib using a biomarker-based approach may be more cost effective.1 These findings were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.  

The researchers evaluated clinical trial results from the Gynecologic Oncology Group (GOG) 218 study (ClinicalTrial Identifier: NCT00262847), which evaluated carboplatin/paclitaxel with or without bevacizumab, including bevacizumab maintenance therapy in the bevacizumab-containing arm, in patients with newly diagnosed ovarian cancer, and the SOLO1 study (ClinicalTrial.gov Identifier: NCT01844986), which evaluated single-agent olaparib in patients with BRCA-mutated ovarian cancer following first-line, platinum-based chemotherapy. Medication-related data were obtained from Medicare. Incremental cost-effectiveness ratios (ICERs), reported in progression-free life-year saved (PF-LYS), were estimated using TreeAge Pro, which is “a visual modeling application used to build decision trees for analyzing various problems to calculate the expected value of different strategies and choose the optimal path.” 2

Related Articles

Among the study findings, bevacizumab maintenance therapy in patients with a deleterious BRCA mutation was associated with an ICER of $565,362 PF-LYS corresponding to a 20-month median PFS. In comparison, for the same group, olaparib maintenance therapy had estimated ICERs of $697,136, $495,938, and $409,710 PF-LYS, corresponding to 6-, 10-, and 14-month median PFS, respectively. 

The study authors concluded that their “economic model suggests that with a biomarker-driven approach in the use of upfront maintenance treatment for [patients with a] BRCA [mutation], olaparib may contribute less of a financial burden on the health care system.”

Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.

Reference

  1. Wolford JE, Liang SY, Tewari KS, et al. An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer. Presented at: Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 44.
  2. TreeAge Pro Core. TreeAge Pro website. https://www.oit.va.gov/Services/TRM/ToolPage.aspx?tid=7017. Accessed March 14, 2019.